AstraZeneca announces that the efficacy rating of its COVID-19 vaccine candidate has been lowered to 76%, following new analyses of the trial run in the United States. Earlier in the week, the company had been criticized for advertising its vaccine with a 79% efficacy rating using what critics claimed was outdated data.
AstraZeneca announces the efficacy rating of its COVID-19 vaccine candidate has been lowered to 76%, following new analyses of the trial run in the United States. Earlier in the week, the establishment had been criticized for advertising the vaccine with a 79% efficacy rating using what critics claimed was outdated data. [https:--www.reuters.com-article-us-health-coronavirus-astrazeneca-usa-idUSKBN2BH03H (Reuters)] Oxford–AstraZeneca COVID-19 vaccine
AstraZeneca announces the efficacy rating of its COVID-19 vaccine candidate has been lowered to 76%, following new analyses of the trial run in the United States. Earlier in the week, the establishment had been criticized for advertising the vaccine with a 79% efficacy rating using what critics claimed was outdated data.
AstraZeneca announces thatthe efficacy rating of its COVID-19 vaccine candidate has been lowered to 76%, following new analyses of the trial run in the United States. Earlier in the week, the company had been criticized for advertising its vaccine with a 79% efficacy rating using what critics claimed was outdated data.
